About
ASCENDO Biotechnology is a clinical-stage biopharmaceutical company developing immunotherapies that target the innate immune system via the TLT-1/CD11b checkpoint pathway to treat solid tumors resistant to existing therapies and autoimmune diseases.
Explore ASCENDO Biotechnology's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.